Albert Bourla, Pfizer CEO (Efren Landaos/Sipa USA/Sipa via AP Images)

Pfiz­er no longer go­ing to con­duct in­ter­im analy­sis for Duchenne gene ther­a­py study by end of year

Pfiz­er no longer plans to read out an in­ter­im analy­sis on its Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py pro­gram by the end of the year, it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.